Manufacturer VerifiedFrance

Vetoquinol S.A.

Vetoquinol

Vetoquinol is a fiercely independent, family-influenced French animal health company that has steadfastly pursued an "Essential Products" focused strategy since its founding in 1933. Headquartered in Lure, Bourgogne-Franche-Comté, France, Vetoquinol generated EUR 525.7 million in 2025 revenue, employing 2,486 employees across 5 integrated production sites. Companion animals now represent 70% of total revenue, anchored by Vetoquinol's legendary 75.8% gross purchasing margin—one of the highest in the industry—achieved through the obsessive vertical integration of its flagship "LILAS" autonomous dry forms production complex in Lure, where all oral solid dosage products are manufactured end-to-end in a completely self-contained, highly automated environment.

Strengths:
• Extraordinary Manufacturing Efficiency: 75.8% gross purchasing margin—among the highest in the global animal health industry—driven by the LILAS complex's fully autonomous solid dosage production
• Companion Animal Purity: 70% of revenue from companion animals, with deep specialization in cardiology, nephrology (Ipakitine), and hepatology (Zentonil)
• Financial Independence: Debt-averse, family-influenced governance with zero reliance on leverage-fueled M&A, generating EUR 72 million in free cash flow in 2025
• Veterinarian Trust: Multi-decade relationships with European veterinary practitioners built on consistent product quality and clinical reliability
• Lean Operating Model: 5 focused production sites globally, each optimized for specific dosage forms, avoiding the complexity and overhead of sprawling multi-site networks
Weaknesses:
• Sub-Scale Revenue Base: At EUR 525.7M, Vetoquinol's absolute R&D budget is materially smaller than competitors, limiting investment in novel biologics and next-generation therapeutics
• Geographic Concentration: Heavy reliance on European markets (particularly France) creates vulnerability to regional economic downturns and regulatory changes
• Limited Innovation Pipeline: The "Essential Products" strategy, while profitable, has resulted in a conservative R&D pipeline with few disruptive innovations compared to larger competitors

Business Nature

Vetoquinol is a fiercely independent, family-influenced French animal health company founded in 1933, operating with a distinct "Essential Products" focused strategy. The company eschews the debt-fueled mega-M&A approach of its peers, instead concentrating all its resources on a carefully curated portfolio of core therapeutic products.

Its industrial crown jewel is the "LILAS" complex in Lure, France—a state-of-the-art autonomous dry forms production unit housing over 300 employees, where all oral solid dosage products including its market-leading hepatology, urology, and cardiovascular tablets are manufactured from raw material blending through compression, coating, and sealed packaging in a completely self-contained, highly automated environment. This obsessive control over solid dosage manufacturing yields an extraordinary 75.8% gross purchasing margin. In total, Vetoquinol operates 5 integrated production sites globally.

Core Business Areas

Companion Animal Core Products — Core Business
• Cardiology & Hypertension: cardiovascular therapeutics
• Nephrology & Urology: Ipakitine for chronic kidney disease
• Hepatology: Zentonil for liver support
• Anti-infectives: Marbofloxacin-based antibiotics
• Anti-inflammatories & Pain Management
• Nutritional Supplements

Industry Rankings

9Top 10 Veterinary Pharmaceuticals & Pet Healthcare Manufacturers & Suppliers

Mfr

Corporate Report

Vetoquinol S.A. is a France-based independent animal health pharmaceutical company headquartered in Lure, Bourgogne-Franche-Comté. Founded in 1933, Vetoquinol has remained fiercely independent for over 90 years. In 2025, the company generated EUR 525.7 million in global revenue, employing 2,486 people across 5 integrated production sites, with products sold in over 100 countries and companion animals representing 70% of total revenue.

Core Business

Vetoquinol's "Essential Products" strategy focuses on high-prescription-rate therapeutic categories where established clinical trust and manufacturing consistency create durable competitive moats. Its core portfolio spans cardiology and hypertension, nephrology (Ipakitine—a leading phosphate binder for feline chronic kidney disease), hepatology (Zentonil), and marbofloxacin-based anti-infectives. Companion animal products now represent 70% of total revenue, reflecting a successful strategic pivot from the company's historical mixed-species portfolio.

Global Presence

Vetoquinol operates 5 integrated production sites globally, with the flagship "LILAS" complex in Lure, France serving as the manufacturing and innovation centerpiece. The LILAS facility's autonomous dry forms production unit—employing over 300 specialists—manufactures all oral solid dosage products from raw material blending through sealed packaging in a fully self-contained environment, yielding an extraordinary 75.8% gross purchasing margin. Products are distributed to over 100 countries through 24 direct subsidiaries and 60+ distribution partners, with particularly strong market positions in Europe and growing presence in North America.

Key Strengths

• Industry-leading 75.8% gross purchasing margin driven by fully autonomous LILAS manufacturing complex
• 70% companion animal revenue concentration with deep specialization in cardiology, nephrology, and hepatology
• 90+ years of independent operation with zero reliance on leverage-fueled M&A
• EUR 72 million in free cash flow generation (2025) providing organic growth funding
• Multi-decade veterinary practitioner trust built on consistent product quality and clinical reliability

VerityRank Score

VerityRank Score of 88/100

VerityRank Score

88/ 100

Based on market presence, financial scale, operational capacity, and brand strength.

Quick Facts

Headquarters

Lure, Bourgogne-Franche-Comté, France

Founded

1933

Employees

2,486

Factories

5 integrated production sites globally

Listing

Euronext Paris: VETO

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website Euronext Paris: VETO , Vetoquinol Official Website
Euronext — Vetoquinol (VETO)
Wikipedia — Vetoquinol

Back to Rankings